Abstract Library

#3111 Patient travel challenges in the rra of PPRT

Introduction: PRRT has been used for the treatment of advanced somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors. Most commonly used forms of PRRT are Lutetium 177 labelled DOTATATE (Lutathera, Advanced Accelerator Applications, a Novartis company) which was recently approved by U.S. Food and Drug Administration (FDA) and Yttrium 90 labelled DOTATATE. In our experience, it is not uncommon for patients recently treated with PRRT to be stopped by United States Customs and Border Protection (CBP) officers while traveling, due to the detection of residual radiation activity.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kendi A

Authors: Kendi A, Halfdanarson T, Naraev B, Mercer D, Underwood J,

Keywords: theranostics, PRRT, lutetium-177-dotatate,

#2013 Optimizing Reconstruction Algorithm to Improve Quality of Post-PRRT Yittrium-90 PET Scan

Introduction: 90Y is commonly used in PRRT for NET. It has no gamma photon in its emission that significantly limits post-therapy imaging and dosimetry. Other than Bremsstrahlung imaging which bears hereditary drawbacks of poor resolution, PET scan has been used for post-PRRT imaging. However, in daily clinical practice, due to extremely low abundance of positron emission per decay and patient’s intolerability of prolonged scan time, it is very difficult to obtain a scan with decent quality.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Yan S

Authors: Yan S, Lim G,

Keywords: PRRT, PET scan, Yttrium 90, neuroendocrine tumor,